Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024
Relmada Therapeutics (Nasdaq: RLMD), a late-stage biotechnology company focusing on central nervous system (CNS) diseases, has announced its plans to host a conference call and webcast on August 7, 2024, at 4:30 PM ET. The event will discuss recent business progress and financial results for the second quarter ended June 30, 2024.
Participants can join the call using US dial-in 1-800-717-1738 or international dial-in 1-646-307-1865, with conference code 39584. Alternatively, they can use the 'Call me™' technology for instant telephone access. A webcast replay will be available in the Investors section of Relmada's website after the event.
Relmada Therapeutics (Nasdaq: RLMD), un'azienda biotecnologica in fase avanzata che si concentra sulle malattie del sistema nervoso centrale (SNC), ha annunciato i suoi piani di tenere una conferenza telefonica e una trasmissione in diretta il 7 agosto 2024, alle 16:30 ET. L'evento discuterà i recenti progressi aziendali e i risultati finanziari per il secondo trimestre concluso il 30 giugno 2024.
I partecipanti possono unirsi alla chiamata utilizzando il numero americano 1-800-717-1738 o il numero internazionale 1-646-307-1865, con il codice conferenza 39584. In alternativa, possono utilizzare la tecnologia 'Call me™' per un accesso telefonico immediato. Una replica della trasmissione sarà disponibile nella sezione dedicata agli Investitori del sito web di Relmada dopo l'evento.
Relmada Therapeutics (Nasdaq: RLMD), una empresa de biotecnología en etapa avanzada que se centra en enfermedades del sistema nervioso central (SNC), ha anunciado sus planes para realizar una llamada de conferencia y una transmisión en vivo el 7 de agosto de 2024, a las 4:30 PM ET. El evento discutirá los avances recientes en el negocio y los resultados financieros del segundo trimestre que finalizó el 30 de junio de 2024.
Los participantes pueden unirse a la llamada utilizando el número de EE. UU. 1-800-717-1738 o el número internacional 1-646-307-1865, con el código de conferencia 39584. Alternativamente, pueden utilizar la tecnología 'Call me™' para acceso telefónico instantáneo. Una repetición de la transmisión estará disponible en la sección de Inversores del sitio web de Relmada después del evento.
Relmada Therapeutics (Nasdaq: RLMD)는 중추 신경계(CNS) 질환에 집중하는 후기 단계 생명공학 회사로, 2024년 8월 7일 오후 4:30 ET에 컨퍼런스 콜 및 웹캐스트를 개최할 계획을 발표했습니다. 이 이벤트는 2024년 6월 30일로 종료된 2분기의 최근 비즈니스 진행 상황과 재무 결과에 대해 논의할 것입니다.
참가자는 미국 전용 전화번호 1-800-717-1738 또는 국제 전화번호 1-646-307-1865를 사용하여 전화에 참여할 수 있으며, 회의 코드 39584를 입력하면 됩니다. 또는 'Call me™' 기술을 사용하여 즉각적인 전화 접근을 할 수 있습니다. 이벤트 후에는 Relmada 웹사이트 투자자 섹션에서 웹캐스트 재생이 가능합니다.
Relmada Therapeutics (Nasdaq: RLMD), une entreprise de biotechnologie en phase avancée se concentrant sur les maladies du système nerveux central (SNC), a annoncé ses projets d'organiser une conférence téléphonique et un webinaire le 7 août 2024 à 16h30 ET. L'événement traitera des récents progrès de l'entreprise et des résultats financiers pour le deuxième trimestre clos le 30 juin 2024.
Les participants peuvent rejoindre l'appel en composant le numéro américain 1-800-717-1738 ou le numéro international 1-646-307-1865, avec le code de conférence 39584. Alternativement, ils peuvent utiliser la technologie 'Call me™' pour un accès téléphonique instantané. Une rediffusion du webinaire sera disponible dans la section Investisseurs du site Web de Relmada après l'événement.
Relmada Therapeutics (Nasdaq: RLMD), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das sich auf Erkrankungen des zentralen Nervensystems (ZNS) konzentriert, hat seine Pläne für eine Telefonkonferenz und einen Webcast am 7. August 2024 um 16:30 Uhr ET bekannt gegeben. Bei der Veranstaltung werden die jüngsten Fortschritte im Geschäft sowie die finanziellen Ergebnisse für das zweite Quartal zum 30. Juni 2024 besprochen.
Teilnehmer können sich über die US-Wahlnummer 1-800-717-1738 oder die internationale Wahlnummer 1-646-307-1865 unter Eingabe des Konferenzcodes 39584 in die Telefonkonferenz einwählen. Alternativ können sie die 'Call me™'-Technologie für einen sofortigen telefonischen Zugang nutzen. Eine Wiederholung des Webcasts wird nach der Veranstaltung im Investorenbereich der Website von Relmada verfügbar sein.
- None.
- None.
CORAL GABLES, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Wednesday, August 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024.
Conference Call and Webcast Information:
Date: Wednesday, August 7, 2024 at 4:30 PM ET
Participant Dial-in (US): 1-800-717-1738
Participant Dial-in (International): 1-646-307-1865
Conference: 39584
Webcast Access: Click Here
The conference call utilizes the “Call me™” technology
- https://emportal.ink/3zo6zXz
- Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link, above, for instant telephone access to the event.
- Call me™ link will be made active 15 minutes prior to scheduled start time.
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.
Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com
FAQ
When will Relmada Therapeutics (RLMD) report its Q2 2024 financial results?
How can investors access Relmada Therapeutics' (RLMD) Q2 2024 earnings call?
Will there be a replay available for Relmada Therapeutics' (RLMD) Q2 2024 earnings call?
What period will Relmada Therapeutics' (RLMD) upcoming financial results cover?
